Zealand boss considers several new indications for blood sugar remedy
CEO of Zealand Pharma, Emmanuel Dulac, reports that the company is investigating several possible indications for the company's blood sugar drug dasiglucagon, after the firm has started new phase 2 studies with a new indication.
Zealand Pharma CEO Emmanuel Dulac isn't holding back with the further development of the company's blood sugar remedy dasiglucagon, even though the drug is yet FDA approved in its first indication.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
